Literature DB >> 10828897

Development of diagnostic thresholds for automated self-measurement of blood pressure in adults. First International Consensus Conference on Blood Pressure Self-Measurement.

J A Staessen1, L Thijs.   

Abstract

Blood pressure is usually measured by conventional sphygmomanometry, a procedure fraught with many potential sources of error. Automated techniques of measurement, such as ambulatory monitoring and self-measurement, reduce the limitations of conventional sphygmomanometry. However, the diagnostic thresholds applicable for conventional sphygmomanometry cannot be extrapolated to automated measurements. During the past 10 years criteria for normality have gradually been developed for ambulatory blood pressure monitoring. First, the distributions of the ambulatory blood pressure in normotensive subjects and in untreated hypertensive patients who had initially been classified on the basis of their conventional blood pressure were studied. Second, epidemiological studies were performed to investigate the distribution of the conventional and ambulatory blood pressures in the population at large. Third, authors of several studies have now validated the preliminary thresholds for ambulatory monitoring against left ventricular hypertrophy, other signs of target-organ damage and the incidence of cardiovascular complications. Finally, authors of clinical trials investigated whether it is beneficial to patients and cost-effective to diagnose and treat hypertension on the basis of ambulatory monitoring rather than under the sole guidance of conventional sphygmomanometry. For systolic/diastolic measurements, the upper limits of normotension include 130/80, 135/85 and 120/70 mmHg for the 24 h, daytime and night-time blood pressures, respectively. Whereas for ambulatory monitoring a large body of evidence currently supports the proposed diagnostic thresholds, for the self-recorded blood pressure, to a large extent, this evidence must still be collected. In pursuing this goal, the methods applied for ambulatory monitoring may serve as a template. On the basis of a meta-analysis of summary statistics of published articles and a meta-analysis of data from individual subjects, 135/85 mmHg is likely to be the upper limit of normality for the self-measured blood pressure. Obviously, this threshold is preliminary and must be further validated in prognostic studies. However, the present proposal could guide clinicians who wish to use self-measurement to refine the diagnosis and the management of hypertension based on conventional sphygmomanometry.

Entities:  

Mesh:

Year:  2000        PMID: 10828897

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  5 in total

Review 1.  ABC of hypertension: Blood pressure measurement. Part IV-automated sphygmomanometry: self blood pressure measurement.

Authors:  E O'Brien; G Beevers; G Y Lip
Journal:  BMJ       Date:  2001-05-12

Review 2.  The role of home BP monitoring: Answers to 10 common questions.

Authors:  Sonal J Patil; Richelle J Koopman; Jeffery Belden; Michael LeFevre
Journal:  J Fam Pract       Date:  2019 Jan/Feb       Impact factor: 0.493

3.  Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study).

Authors:  Alan J Zillich; Jason M Sutherland; Patty A Kumbera; Barry L Carter
Journal:  J Gen Intern Med       Date:  2005-12       Impact factor: 5.128

4.  Telemedicine cardiovascular risk reduction in veterans.

Authors:  S Dee Melnyk; Leah L Zullig; Felicia McCant; Susanne Danus; Eugene Oddone; Lori Bastian; Maren Olsen; Karen M Stechuchak; David Edelman; Susan Rakley; Miriam Morey; Hayden B Bosworth
Journal:  Am Heart J       Date:  2013-02-28       Impact factor: 4.749

5.  Racial differences in the effect of a telephone-delivered hypertension disease management program.

Authors:  George L Jackson; Eugene Z Oddone; Maren K Olsen; Benjamin J Powers; Janet M Grubber; Felicia McCant; Hayden B Bosworth
Journal:  J Gen Intern Med       Date:  2012-08-03       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.